SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination
Background: Patients with kidney disease on Hemodialysis (HD) are susceptible to Coronavirus Disease (COVID-19) due to multiple risk factors. Aim: This study aims to report the prevalence of antibodies against SARS-CoV-2 among patients on hemodialysis before vaccination in Brazil and to compare with...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Brazilian Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1413867024000187 |
| _version_ | 1831888902363807744 |
|---|---|
| author | Alanna Calheiros Santos Vanessa Duarte da Costa Lucas Lima da Silva Juliana Custódio Miguel Rodrigo Jardim Alberto Martín Rivera Dávila Vanessa Salete de Paula Juliana Gil Melgaço Barbara Vieira do Lago Livia Melo Villar |
| author_facet | Alanna Calheiros Santos Vanessa Duarte da Costa Lucas Lima da Silva Juliana Custódio Miguel Rodrigo Jardim Alberto Martín Rivera Dávila Vanessa Salete de Paula Juliana Gil Melgaço Barbara Vieira do Lago Livia Melo Villar |
| author_sort | Alanna Calheiros Santos |
| collection | DOAJ |
| description | Background: Patients with kidney disease on Hemodialysis (HD) are susceptible to Coronavirus Disease (COVID-19) due to multiple risk factors. Aim: This study aims to report the prevalence of antibodies against SARS-CoV-2 among patients on hemodialysis before vaccination in Brazil and to compare with clinical, demographic, and laboratory data. Methods: Blood samples from 398 Chronic Kidney Disease (CKD) patients treated in three different private institutions in Rio de Janeiro State, Brazil were submitted to the total anti-SARS-CoV-2 testing. Kidney, liver, and hematological markers were also determined. Respiratory samples were tested by real-time PCR for SARS-CoV-2 RNA and positive samples were subjected to high-throughput sequencing on the MinION device. Results: Overall, anti-SARS-CoV-2 prevalence was 54.5 % (217/398) and two individuals had SARS-CoV-2 RNA with variant B.1.1. High anti-SARS-CoV-2 seroprevalence was found in male gender and those with hospital admission in the last 3-months before the inclusion in the study. Lower red blood cell count was observed in the anti-SARS-CoV-2 seropositive group. High levels of anti-SARS-CoV-2 were found in those who reported symptoms, had low levels of eosinophils and low hematocrit, and who practiced physical activity. Conclusion: High prevalence of anti-SARS-CoV-2 was found in CKD patients before the universal immunization in Brazil suggesting that dialysis patients were highly exposed to SARS-CoV-2. |
| first_indexed | 2024-04-24T20:06:51Z |
| format | Article |
| id | doaj.art-8031a4c646e944fea75a83737a3ac194 |
| institution | Directory Open Access Journal |
| issn | 1413-8670 |
| language | English |
| last_indexed | 2025-03-22T00:26:40Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Brazilian Journal of Infectious Diseases |
| spelling | doaj.art-8031a4c646e944fea75a83737a3ac1942024-05-15T04:21:49ZengElsevierBrazilian Journal of Infectious Diseases1413-86702024-03-01282103735SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccinationAlanna Calheiros Santos0Vanessa Duarte da Costa1Lucas Lima da Silva2Juliana Custódio Miguel3Rodrigo Jardim4Alberto Martín Rivera Dávila5Vanessa Salete de Paula6Juliana Gil Melgaço7Barbara Vieira do Lago8Livia Melo Villar9Instituto Oswaldo Cruz (FIOCRUZ), Laboratório Brasileiro de Referência em Hepatites Virais, Rio de Janeiro, RJ, BrazilInstituto Oswaldo Cruz (FIOCRUZ), Laboratório Brasileiro de Referência em Hepatites Virais, Rio de Janeiro, RJ, BrazilInstituto Oswaldo Cruz (FIOCRUZ), Laboratório Brasileiro de Referência em Hepatites Virais, Rio de Janeiro, RJ, BrazilInstituto Oswaldo Cruz (FIOCRUZ), Laboratório Brasileiro de Referência em Hepatites Virais, Rio de Janeiro, RJ, BrazilInstituto Oswaldo Cruz (FIOCRUZ), Laboratório de Biologia Computacional e de Sistemas, Programa de Pós-Graduação em Biodiversidade e Saúde, Rio de Janeiro, RJ, BrazilInstituto Oswaldo Cruz (FIOCRUZ), Laboratório de Biologia Computacional e de Sistemas, Programa de Pós-Graduação em Biodiversidade e Saúde, Rio de Janeiro, RJ, BrazilInstituto Oswaldo Cruz (FIOCRUZ), Laboratório de Virologia Molecular e Parasitologia, Rio de Janeiro, RJ, BrazilBio-Manguinhos (FIOCRUZ), Laboratório de Tecnologia Imunológica, Rio de Janeiro, RJ, BrazilInstituto Oswaldo Cruz (FIOCRUZ), Laboratório Brasileiro de Referência em Hepatites Virais, Rio de Janeiro, RJ, BrazilInstituto Oswaldo Cruz (FIOCRUZ), Laboratório Brasileiro de Referência em Hepatites Virais, Rio de Janeiro, RJ, Brazil; Corresponding author.Background: Patients with kidney disease on Hemodialysis (HD) are susceptible to Coronavirus Disease (COVID-19) due to multiple risk factors. Aim: This study aims to report the prevalence of antibodies against SARS-CoV-2 among patients on hemodialysis before vaccination in Brazil and to compare with clinical, demographic, and laboratory data. Methods: Blood samples from 398 Chronic Kidney Disease (CKD) patients treated in three different private institutions in Rio de Janeiro State, Brazil were submitted to the total anti-SARS-CoV-2 testing. Kidney, liver, and hematological markers were also determined. Respiratory samples were tested by real-time PCR for SARS-CoV-2 RNA and positive samples were subjected to high-throughput sequencing on the MinION device. Results: Overall, anti-SARS-CoV-2 prevalence was 54.5 % (217/398) and two individuals had SARS-CoV-2 RNA with variant B.1.1. High anti-SARS-CoV-2 seroprevalence was found in male gender and those with hospital admission in the last 3-months before the inclusion in the study. Lower red blood cell count was observed in the anti-SARS-CoV-2 seropositive group. High levels of anti-SARS-CoV-2 were found in those who reported symptoms, had low levels of eosinophils and low hematocrit, and who practiced physical activity. Conclusion: High prevalence of anti-SARS-CoV-2 was found in CKD patients before the universal immunization in Brazil suggesting that dialysis patients were highly exposed to SARS-CoV-2.http://www.sciencedirect.com/science/article/pii/S1413867024000187SARS-CoV-2PrevalenceChronic kidney diseaseSeroepidemiologyCovid-19 pandemic |
| spellingShingle | Alanna Calheiros Santos Vanessa Duarte da Costa Lucas Lima da Silva Juliana Custódio Miguel Rodrigo Jardim Alberto Martín Rivera Dávila Vanessa Salete de Paula Juliana Gil Melgaço Barbara Vieira do Lago Livia Melo Villar SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination Brazilian Journal of Infectious Diseases SARS-CoV-2 Prevalence Chronic kidney disease Seroepidemiology Covid-19 pandemic |
| title | SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination |
| title_full | SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination |
| title_fullStr | SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination |
| title_full_unstemmed | SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination |
| title_short | SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination |
| title_sort | sars cov 2 and dialysis humoral response clinical and laboratory impacts before vaccination |
| topic | SARS-CoV-2 Prevalence Chronic kidney disease Seroepidemiology Covid-19 pandemic |
| url | http://www.sciencedirect.com/science/article/pii/S1413867024000187 |
| work_keys_str_mv | AT alannacalheirossantos sarscov2anddialysishumoralresponseclinicalandlaboratoryimpactsbeforevaccination AT vanessaduartedacosta sarscov2anddialysishumoralresponseclinicalandlaboratoryimpactsbeforevaccination AT lucaslimadasilva sarscov2anddialysishumoralresponseclinicalandlaboratoryimpactsbeforevaccination AT julianacustodiomiguel sarscov2anddialysishumoralresponseclinicalandlaboratoryimpactsbeforevaccination AT rodrigojardim sarscov2anddialysishumoralresponseclinicalandlaboratoryimpactsbeforevaccination AT albertomartinriveradavila sarscov2anddialysishumoralresponseclinicalandlaboratoryimpactsbeforevaccination AT vanessasaletedepaula sarscov2anddialysishumoralresponseclinicalandlaboratoryimpactsbeforevaccination AT julianagilmelgaco sarscov2anddialysishumoralresponseclinicalandlaboratoryimpactsbeforevaccination AT barbaravieiradolago sarscov2anddialysishumoralresponseclinicalandlaboratoryimpactsbeforevaccination AT liviamelovillar sarscov2anddialysishumoralresponseclinicalandlaboratoryimpactsbeforevaccination |